This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
Global Oncology Academy
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
0
- Guest: Vivek Subbiah, MD
What do we need to know about comprehensive genomic profiling and CGP-directed therapies for NSCLC patients?
Facebook Comments